What is the goal of alpha1-antitrypsin deficiency (AATD) management?

Updated: Sep 11, 2020
  • Author: Dora E Izaguirre Anariba, MD, MPH; Chief Editor: John J Oppenheimer, MD  more...
  • Print

Preventing or slowing the progression of lung disease is the major goal of AAT deficiency (AATD) management. Decreasing any proinflammatory stimuli in the alveolus, including smoking, asthma, or respiratory infection, facilitates this goal. Alternatively, augmenting or replacing the deficient enzyme, and thereby moderating inflammatory stimuli, is also important. Most patients are identified only after they develop lung disease, and the goals of treating AATD emphysema are similar to those for treating all forms of emphysema.

To decrease the risk of liver disease, vaccination against hepatitis A and B is recommended.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!